Genetic Technologies Limited
Registered Office
60-66 Hanover Street
Fitzroy
Victoria
3065
Tel: 61-3-9415-1135
Fax: 61-3-9417-2987
Website: http://www.gtg.com.au/
Email: info@gtg.com.au
191 articles about Genetic Technologies Limited
-
GENE Presents Study Involving 200,000 Participants at 2021 San Antonio Breast Cancer Symposium
12/10/2021
Genetic Technologies Limited confirms that the Company’s Director of Clinical Affairs & Medical Education, Erika Spaeth, PhD will be presenting at 2021 San Antonio Breast Cancer Symposium.
-
Genetic Technologies Announces New Partnership and geneType COVID-19 Risk Test Patent Allowance from the USPTO
12/9/2021
Genetic Technologies Limited confirms that the Company’s US patent application for its novel geneType COVID-19 Risk Test has been accepted.
-
GENE Delivers Material 12-Fold Increase in Revenue in the Quarter Ended September 2021
10/4/2021
Genetic Technologies Limited, a global leader in genomics-based tests in health, wellness and serious disease, announces a 12-fold increase in revenue generated during the September 2021 quarter to A$850k1.
-
Genetic Technologies Reports FY21 Results as it Turns the Corner on its Commercialization Strategy
8/31/2021
Genetic Technologies Limited is pleased to provide the financial results for the year ended June 30, 2021.
-
Genetic Technologies Rapidly Accelerating Commercialization Plans
7/26/2021
Genetic Technologies Limited (NASDAQ: GENE, “Company”, “GTG”), a global leader in Genomics based tests in health, wellness and serious disease, is pleased to provide its Quarterly Business Update to the market.
-
Genetic Technologies Continues to Break New Ground as it Advances Development of its Predictive Risk Test for Multiple Cancers & Morbidities
7/9/2021
Genetic Technologies Limited today announced updates on the development of its Predictive Panel Risk Test designed to cover six different cancers including breast and colorectal cancer, prostate and ovarian cancer, pancreatic cancer and melanoma.
-
US Patent Office Grants Foundational Pharmacogenomic Patent
6/11/2021
Genetic Technologies Limited, a diversified Genomics and AI driven preventative health business, has been granted US Patent No. 11,031,098 – ‘Computer Systems and Methods for Genomic Analysis’.
-
Genetic Technologies’ COVID-19 Risk Test Now Available in US through Partnership with Infinity BiologiX
6/1/2021
Test improves COVID-19 prevention and management capabilities for employers, governments, and public health decision makers
-
Genetic Technologies Interview to Air on Bloomberg Television U.S. on the RedChip Money Report®
5/13/2021
Genetic Technologies Limited, a diversified Genomics and AI driven preventative health business, announced an interview with Simon Morriss, CEO, will air on The RedChip Money Report® on the Bloomberg Network in the U.S. on Saturday, May 15th, at 7 p.m. local time in 73M homes across the United States.
-
Genetic Technologies appoints Mike Tonroe as CFO
4/12/2021
Molecular diagnostics company Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”), announces the appointment of Michael Tonroe to the role of Chief Financial Officer, commencing on 28 June 2021.
-
Genetic Technologies Signs Multi-Year US Distribution Agreement for COVID Risk Test
3/4/2021
Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a diversified Genomics and AI-driven preventative health business is pleased to announce a co-exclusive production and distribution rights and license agreement (‘Agreement’) with US-based Infinity BiologiX LLC (‘IBX’), a leading central laboratory providing sample collection and processing,
-
Genetic Technologies Provides Update on its COVID-19 Disease Severity Risk Test and Expansion into Germline Testing
1/21/2021
Molecular diagnostics company Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”), provides the following update to the market on further development on the COVID-19 serious disease risk Polygenic Risk Score Test (COVID-19 PRS Test) and expansion of the Company’s offering to include Germline Testing division.
-
Genetic Technologies Interview Aired on Bloomberg International on the RedChip Money Report
11/23/2020
Molecular diagnostics company Genetic Technologies Limited is pleased to announce an interview with its interim-CEO, Dr. Jerzy Muchnicki aired on The RedChip Money Report television program.
-
Genetic Technologies to Hold Investor Webinar and Q&A Session on November 19
11/17/2020
Molecular diagnostics company Genetic Technologies Limited (ASX: GTG; Nasdaq: GENE, “Company”) is pleased to announce its interim-CEO, Dr. Jerzy Muchnicki, will share insight into the company’s recent developments during an investor webinar on Thursday, November 19, 2020 at 4:15 p.m. ET. A live Q&A session with Dr. Muchnicki will follow the presentation. To participate in the webinar, please register at: https://www.redchip.com/cor
-
Genetic Technologies Provides Update on COVID-19 Risk Test
10/1/2020
Molecular diagnostics company Genetic Technologies Ltd, provides the following update to the market on the development of the Company’s COVID-19 Risk Test.
-
Genetic Technologies Announces Closing of $5.1 Million Registered Direct Offering
7/20/2020
Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE) (the “Company”), a leader in the development of genetic risk assessment tests, today announced the closing of its previously announced registered direct offering of 1,025,000 American Depositary Shares (“ADSs”)
-
Genetic Technologies Announces $5.1 Million Registered Direct Offering
7/16/2020
Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE) (the “Company”), a leader in the development of genetic risk assessment tests, today announced that it has entered into definitive agreements with several institutional investors for the purchase and sale in a registered direct offering of 1,025,000 American Depositary Shares (“ADSs”), each representing six hundred (600) of the Company’s ordinary shares, at a purchase price of $5.00 pe
-
Genetic Technologies Provides Update on COVID-19 Disease Severity Test
7/15/2020
Highlights Genetic Technologies has filed a provisional patent for its COVID-19 Severity Risk Test with the Patent Office in Australia The COVID-19 Severity Risk Test comprises a polygenic risk test (PRS) and assessment for clinical risk factors Genetic Technologies has completed the design and request for initial production of the SNP (Single Nucleotide Polymorphism) panel required to process the polygenic risk test portion of the COVID-19 Severity Risk Test from US-based Thermo Fisher Sc
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for July 15, 2020.
-
Genetic Technologies CEO to Participate in Investor Webinar and Q&A Session on June 24, 2020
6/23/2020
Molecular diagnostics company Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE) (the “Company”) is pleased to announce that its interim-CEO Dr. George Muchnicki will share insight into the Company’s recent developments during an investor webinar, hosted by RedChip Companies, on Wednesday, June 24, 2020 at 4:00 p.m. ET. A live Q&A session with Dr. Muchnicki will follow the presentation.